EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).

Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, Francesca Maria Rizzo, Chiara Maria Grana, Mauro Cives, Antongiulio Faggiano, Annibale Versari, Salvatore Tafuto, Nicola Fazio, Annamaria Colao, Federica Scalorbi und 3 weitere

Journal of Endocrinological Investigation · 2024

DOI: 10.1007/s40618-024-02448-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von Francesco Panzuto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical-Surgical Sciences and Translational Medicine, Digestive Disease Unit, Sapienza University of Rome, Sant'Andrea University Hospi…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Intestinal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This paper outlines the consensus of the Italian Association for Neuroendocrine Tumors(Itanet), the Italian Association of Nuclear Medicine (AIMN), the Italian Society of Endocrinology (SIE), and the Italian Association of Medical Oncology (AIOM) on treating neuroendocrine neoplasms (NENs)with radioligand therapy (RLT).

Methods

A list of 10 questions regarding using RLT ingastroenteropancreatic neuroendocrine tumors (GEP-NETs) was addressed after a careful review of theavailable literature. compiling information from the MEDLINE database, augmented with expert opinionsand recommendations, aligns with the latest scientific research and the author’s extensive knowledge.The recommendations are evaluated using the GRADE system, showcasing the level of evidence andthe strength of the recommendations. Results and Conclusions Specifically, this paper focuses on thesubcategories of well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) thatexpress somatostatin receptors and are considered suitable for RLT, according to internationalguidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsIntestinal NeoplasmsStomach NeoplasmsRadiopharmaceuticalsHumansItalyConsensusNuclear MedicineSocieties, MedicalEndocrinologyMedical Oncology

Stichwörter der Autor:innen

ChemotherapyEverolimusGuidelinesNeuroendocrine tumorsPeptide-receptor radionuclide therapyRadioligand therapySomatostatin analogsSunitinib

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Medical-Surgical Sciences and Translational Medicine, Digestive Disease Unit, Sapienza University of Rome, Sant'Andrea University Hospital, ENETS Center of Excellence, Rome, Italy.
  • Endocrinology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genova, Italy.
  • Endocrinology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Nuclear Medicine - PET and Therapy Unit, Dept. of Health Services AORN dei Colli, Naples, Italy.
  • Oncology and Breast Unit, Ospedale "A. Perrino", Brindisi, Italy.
  • Radiometabolic Therapy, Nuclear Medicine Division, IRCCS IEO European Institute of Oncology, Milano, Italy.

Förderung

  • Università degli Studi di Roma La Sapienza

Zitieren

APA

Panzuto, F., Albertelli, M., De Rimini, M. L., Rizzo, F. M., Grana, C. M., Cives, M., Faggiano, A., Versari, A., Tafuto, S., Fazio, N., Colao, A., Scalorbi, F., Ferone, D., Cinieri, S., & Maccauro, M. (2024). Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02448-6

Vancouver

Panzuto F, Albertelli M, De Rimini ML, Rizzo FM, Grana CM, Cives M, et al. Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02448-6

BibTeX
@article{Panzuto2024,
  author = {Panzuto, Francesco and Albertelli, Manuela and De Rimini, Maria Luisa and Rizzo, Francesca Maria and Grana, Chiara Maria and Cives, Mauro and Faggiano, Antongiulio and Versari, Annibale and Tafuto, Salvatore and Fazio, Nicola and Colao, Annamaria and Scalorbi, Federica and Ferone, Diego and Cinieri, Saverio and Maccauro, Marco},
  title = {Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  doi = {10.1007/s40618-024-02448-6}
}
Kostenlos starten →